Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Balversais a new oral anti-cancer drug targeting FGFR, which is specially design···【more】
Release date：2024-08-26Recommended：243
Balversais an oral tyrosine kinase inhibitor for the treatment of non-small cell···【more】
Release date：2024-08-26Recommended：211
Alpelisib has demonstrated a unique efficacy against PIK3CA mutations in HR/HER2···【more】
Release date：2024-08-23Recommended：222
Patients with HR/HER2- advanced breast cancer harboring PIK3CA mutations were si···【more】
Release date：2024-08-23Recommended：305
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic···【more】
Release date：2024-08-23Recommended：253
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly i···【more】
Release date：2024-08-23Recommended：251
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib ···【more】
Release date：2024-08-23Recommended：185
As a PIK3CA inhibitor, Alpelisib works synergistically with fulvestrant to signi···【more】
Release date：2024-08-23Recommended：243
Alpelisib effectively inhibits the proliferation of HR/HER2- breast cancer cells···【more】
Release date：2024-08-23Recommended：239
The combination of Alpelisib and fulvestrant specifically targeted patients with···【more】
Release date：2024-08-23Recommended：225
Koselugois a multifunctional targeted therapy drug, which can be used as a small···【more】
Release date：2024-08-23Recommended：239
Koselugo is a targeted therapy that targets specific cancers by inhibiting the a···【more】
Release date：2024-08-23Recommended：270
